Klin Onkol 1991; 4(4): 108-110.
The study evaluates the results of chemotherapy in the patients with advanced, hormon-resistant prostatic carcinoma. In the treatment there were used the following therapeutic schemes: adriamycin + cyclophosphamide + methotrexate, cyclophosphamide + cis-platinum + 5-fluorouracil, cyclophosphamide + methotrexate, cyclophosphamide. The results of the chemotherapy could be evaluated in 15 of 20 patients. Parcial remision was achieved in 2 patients (13,3%) with duration 12 and 17 weeks resp. and 4 patients (26,7%) had the stable disease (according to National Prostatic Cancer Project criteria). There were complications - leucopenia and trombocytopénia in 3 patients (20%), one of them died because of brain hemorrhage. Results are in agreement with reports from papers, that chemotherapy is of little effect in hormonal resistant prostatic carcinoma.
